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Abstract
Background: Glioblastoma Multiforme (GBM) is the most lethal form of brain tumor. Efficient DNA repair and anti-apoptotic
mechanisms are making glioma treatment difficult. Proteases such as MMP9, cathepsin B and urokinase plasminogen
activator receptor (uPAR) are over expressed in gliomas and contribute to enhanced cancer cell proliferation. Non-
homologous end joining (NHEJ) repair mechanism plays a major role in double strand break (DSB) repair in mammalian
cells.
Methodology/Principal Findings: Here we show that silencing MMP9 in combination with uPAR/cathepsin B effects NHEJ
repair machinery. Expression of DNA PKcs and Ku70/80 at both mRNA and protein levels in MMP9-uPAR (pMU) and MMP9-
cathepsin B (pMC) shRNA-treated glioma xenograft cells were reduced. FACS analysis showed an increase in apoptotic peak
and proliferation assays revealed a significant reduction in the cell population in pMU- and pMC-treated cells compared to
untreated cells. We hypothesized that reduced NHEJ repair led to DSBs accumulation in pMU- and pMC-treated cells,
thereby initiating cell death. This hypothesis was confirmed by reduced Ku70/Ku80 protein binding to DSB, increased comet
tail length and elevated cH2AX expression in treated cells compared to control. Immunoprecipitation analysis showed that
EGFR-mediated lowered DNA PK activity in treated cells compared to controls. Treatment with pMU and pMC shRNA
reduced the expression of DNA PKcs and ATM, and elevated cH2AX levels in xenograft implanted nude mice. Glioma cells
exposed to hypoxia and irradiation showed DSB accumulation and apoptosis after pMU and pMC treatments compared to
respective controls.
Conclusion/Significance: Our results suggest that pMU and pMC shRNA reduce glioma proliferation by DSB accumulation
and increase apoptosis under normoxia, hypoxia and in combination with irradiation. Considering the radio- and chemo-
resistant cancers favored by hypoxia, our study provides important therapeutic potential of MMP9, uPAR and cathepsin B
shRNA in the treatment of glioma from clinical stand point.
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Introduction
Glioblastoma Multiforme (GBM) is a highly malignant tumor of
the central nervous system with a median survival rate of less than
12 months and with a high rate of recurrence. The genetic
makeup of GBM is complex involving a number of chromosome
aberrations and genetic alterations in several genes [1,2].
Chromosomal double strand breaks (DSBs) caused by genomic
instability are considered to be toxic DNA lesions compared to
others [3]. Stabilization of irradiation (IR)-induced DNA damage
usually fails not only due to an hypoxic environment but also by
the enhanced DNA repair ability of glioma cells [4]. Efficiency of
glioma cells to elevate DNA damage repair, anti-apoptotic
mechanisms and other growth survival signaling pathways
enhance GBM proliferation, and in addition to hypoxia make
treatment of GBM difficult [5,6].
DSBs can be repaired either by non-homologous end joining
(NHEJ) or homologous recombination (HR). In mammalian cells,
NHEJ is the predominant DSB repair mechanism compared to
HR [7]. Both DNA protein kinase catalytic subunit (DNA PKcs)
and ataxia talengiectasia mutated (ATM) belong to the phospha-
tidylinositol kinase family. The serine-threonine kinase activity of
these proteins is involved in cellular functions such as DNA
damage surveillance, transcription and cell cycle progression [8].
DNA PK comprising the DNA PKcs, Ku70 and Ku80, form
complexes at DSBs to initiate repair by NHEJ mechanism.
Proficient repair of DSBs has been associated with over-expression
of DNA PKcs [9]. ATM plays an important role in DNA damage
response (DDR) by facilitating cell cycle arrest or triggering
apoptosis based on the severity of the damage [10]. Growth
signaling proteins such as Epidermal growth factor receptor
(EGFR) are over-expressed in various cancers including GBM
[11,12]. EGFR is shown to physically interact with DNA PK and
regulate its activity [13].
Earlier studies have shown the increased expression levels of
matrix metalloprotease 9 (MMP9) and its correlation with the
PLoS ONE | www.plosone.org 1 October 2011 | Volume 6 | Issue 10 | e26191histological grade of glioma malignancy [14,15]. Moreover,
interaction of MMP9 with the Ku protein at the cell surface of
leukemia cell lines was associated with cell invasion [16].
Urokinase-type plasminogen activator receptor (uPAR) expression
is elevated in many human cancers including GBM and is
indicative of poor prognosis [17]. Urokinase receptors have been
shown to influence the expression of other proteases such as
cathepsin B and MMP9, which are overexpressed in GBM
[18,19]. Furthermore, uPAR interaction with uPA has been shown
to activate a downstream signal cascade involving plasminogen
and MMP, which leads to ECM degradation, the release of growth
factors, and ultimately tumor growth [20,21]. Our earlier studies
clearly demonstrated the efficacy of simultaneous downregulation
of these bicistronic plasmid shRNA constructs in treating tumors
by reducing adhesion, migration and invasion potential and
inducing apoptosis in cancer cells [22–26]. However, none of our
earlier studies have addressed the effect of these bicistronic
constructs on DNA damage response (DDR) and the related
molecular mechanisms involved. Hence, as the first step towards
understanding the signal transduction in DDR in DSB repair, in
the present study, we have used human glioma xenograft cells and
treated them with MMP9+uPAR (pMU) and MMP9+cathepsin B
(pMC) bicistronic plasmid shRNA constructs in both in vitro and in
vivo models.
Here, we have demonstrated the role of MMP9 in combination
with uPAR/cathepsin B in DDR in glioma xenograft cells. Our
results clearly demonstrated that pMU and pMC treatments alter
DNA repair efficiency, induces apoptosis and depletes survival
signals in normoxic, hypoxic and hypoxic+IR exposed glioma
cells.
Results
pMU and pMC treatments regulates non-homologous
end joining (NHEJ) DNA repair proteins
NHEJ repair mechanism accounts for more than 75% of DSB
repair in mammalian cells. To investigate the role of pMU and
pMC treatments in DDR, we analyzed the expression of NHEJ
related proteins DNA PKcs, Ku70 and Ku80. Our results showed
reduced expressions of these proteins in pMU- and pMC-treated
samples at both mRNA and protein levels in 4910 and 5310 cells
(Figure 1A). We also observed that pDNA PKcs T2609 expression,
Figure 1. Downregulation of non homologous end joining DNA repair machinery by pMU and pMC in glioma xenograft cells. A. RT
PCR analysis showing expression of NHEJ related genes in pMU- and pMC-treated 4910 and 5310 glioma cells. GAPDH shows equal loading. Western
blot analysis performed using cell lysates prepared from pMU and pMC silenced 4910 and 5310 glioma cells showing expression of DNA PKcs, pDNA
PKcs, Ku70 and Ku80. GAPDH was analyzed as loading control. Each experiment was repeated 3 times. B. Further, quantification of the Western blots
using ImageJ (NIH) software to determine the levels of these proteins after pMU and pMC treatments is shown. n=3. Values shown are the mean
(6SD). *p,0.05 vs. control. C. Immunoprecipitation (IP) analysis. IP of b1 integrin was immunoprobed with uPAR in both 4910 and 5310 glioma
xenograft cells. IP of uPAR was immunoprobed with MMP9 and cathepsin B in glioma cells. Each experiment was repeated 3 times.
doi:10.1371/journal.pone.0026191.g001
Role of MMP9 and uPAR/Cath B Silencing on NHEJ
PLoS ONE | www.plosone.org 2 October 2011 | Volume 6 | Issue 10 | e26191a marker for NHEJ activation, was significantly reduced in pMU-
and pMC-treated samples in these glioma cells (Figure 1A and 1B).
We observed uPAR interaction with b1 integrin and co-
immunoprecipitation of uPAR with MMP9 and cathepsin B
(Figure 1C). We anticipate that these interactions among MMP9,
uPAR, cathepsin B and b1 integrin demonstrate b1 integrin-
mediated ECM signaling in reduced activity of NHEJ in pMU-
and pMC-treated 4910 and 5310 glioma xenograft cells compared
to untreated cells. Thus, pMU and pMC treatments in glioma
xenograft cells play an important role in cellular signaling
regulating the expression of NHEJ repair machinery.
pMU and pMC treatments inhibit proliferation of 4910
and 5310 glioma xenograft cells
In the present study, BrdU incorporation assay and survival
fraction showed a significant decrease in the proliferation of 4910
and 5310 glioma cells treated with pMU and pMC compared to
control and pSV-treated cells. Cell proliferation by BrdU assay
showed a 45–50% reduced proliferation rate in pMU- and pMC-
treated 4910 and 5310 glioma cells compared to control and pSV
(Supplementary Figure S1A). Survival fraction from the clono-
genic assay showed a 70–80% and 75–80% decrease in colony
forming units after 2 weeks of pMU and pMC treatments
respectively, compared to control and pSV-transfected cells
(Supplementary Figure S1B). We have recently shown the
efficiency of pMU and pMC constructs in downregulating
respective target genes in treated 4910 and 5310 glioma xenograft
cells [26].
pMU and pMC treatments reduce EGFR-mediated DNA
PK activity
EGFR expression plays an important role in proliferation and
survival signals in cells [27]. EGFR interacts with DNA PK and
regulates its activity [13]. As shown in Figures 2A and
Supplementary Figure S1C, the expression of EGFR was
decreased in pMU- and pMC-transfected glioma cells as
compared to the controls. Perinuclear expression and nuclear
internalization of EGFR is brought about by caveolin-1 (Cav-1).
We observed the reduced expression of cav-1 (Figure 2A), integrin
b1 and cSrc [26] in pMU- and pMC-transfected glioma cells
compared with pSV and control. In addition, we investigated the
interaction of EGFR with DNA PK by immunoprecipitation (IP)
analysis. As shown in Figure 2B, IP of DNA PKcs and
immunoprobed with EGFR showed reduced interaction with
EGFR in pMU- and pMC-treated glioma cells compared to
control and pSV-treated samples. Further, IP with EGFR and
immunoblotting with Ku70 and Ku80 showed decreased associ-
ation in pMU- and pMC-treated 5310 glioma xenograft cells
compared to control (Figure 2B). In the present study, we
evaluated the nuclear expression of these proteins. Figure 2C
clearly showed that the nuclear expression of DNA PKcs, Ku70,
Ku80 and EGFR was downregulated after pMU and pMC
treatments. Moreover, the expression of SP1, a known transcrip-
tion factor of DNA PKcs, Ku70 and Ku80, was reduced in pMU-
and pMC-treated glioma cells compared to untreated cells
(Figure 2A). Based on our results, it is very clear that there is a
decreased activity of DNA PK, a key protein complex involved in
initiation of NHEJ repair mechanism after pMU and pMC
treatments in 4910 and 5310 glioma cells.
pMU and pMC treatments inhibit Ku binding to DSBs and
alters expression of DNA damage response (DDR)
proteins
Ku70 and Ku80 binding efficiency to DSBs plays a major role
in the initiation of NHEJ repair mechanism [7]. From our
quantitative analysis of the efficiency of Ku70 and Ku80 binding
to oligonucleotide, it is evident that the ability of Ku70 and Ku80
proteins to bind to the DSBs was significantly reduced in pMU-
and pMC-treated samples in both 4910 and 5310 xenograft cells
(Figure 3A). The binding of Ku70 to DNA was reduced by 50% in
pMU-treated and 45% in pMC-treated 4910 glioma cells
compared to controls. In addition, the binding of Ku80 was
Figure 2. Regulation of DNA PK activity in pMU- and pMC-transfected glioma cells. A. Western blot analysis shows expression of EGFR,
cav-1 and SP1 in pMU- and pMC-treated glioma cells along with control and pSV. B. Immunoprecipitation (IP) analysis. IP of DNA PKcs was
immunoprobed with EGFR in both 4910 and 5310 glioma xenograft cells transfected with pMU and pMC along with control and pSV samples. IP of
EGFR was immunoprobed with Ku70 and Ku80 in pMU and pMC treated glioma cells. IgG shows equal loading. C. Immunoblot analysis of DNA PKcs,
Ku70, Ku80 and EGFR from nuclear lysates was carried out in pMU and pMC silenced 4910 and 5310 glioma xenograft cells. Lamin B was used for
equal loading. Each experiment was repeated 3 times.
doi:10.1371/journal.pone.0026191.g002
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cells compared with controls (Figure 3A). Similar results were
observed in 5310 cells, wherein 60% and 46% of Ku70 and 39%
and 37% of Ku80 binding to DNA were decreased in pMU- and
pMC-treated samples, respectively, compared to controls
(Figure 3A). This result indicates a reduction in the initiation of
NHEJ repair in pMU- and pMC-treated glioma xenograft cells.
These findings further strengthen our earlier findings wherein our
pMU and pMC treatments lowered DNA PK activity in these
glioma xenograft cells.
We also investigated the expression of proteins involved in
homologous recombination (HR) and others such as ATR, pATR
and pBRCA by Western blotting. As shown in Figure 3B, the
expression of ATM, Rad51 and pCHK2 were downregulated in
pMU- and pMC-treated glioma cells compared to control and
pSV. In contrast, pATR expression was elevated in both 4910 and
5310 glioma cells with pMU and pMC treatments compared to
controls (Figure 3B). ATM-mediated repair response to DSBs is
initiated by its binding to DSBs. Co-localization studies of cH2AX
foci and pATM showed reduced interaction in pMU- and pMC-
Figure 3. Inhibition of Ku activity and DDR related protein expression by pMU- and pMC-treated glioma xenograft cells. A. Ku70/80
DNA repair protein assay performed by using Active motif kit shows Ku70 and Ku80 protein binding to oligonucleotide in pMU- and pMC- treated
4910 and 5310 glioma xenograft cells along with control and pSV, respectively. Error bars indicate 6SD. * significant at p,0.05 Vs control. B.
Immunoblot analysis showsexpression of key proteins involved in homologous recombination and DNA repair, such as ATM, pATM, RAD51, CHK2,
pCHK2, ATR, pATR and pBRCA in both 4910 and 5310 glioma cells treated with pMU and pMC. Survival pathway protein such as ERK, pERK AKT and
pAKT were analyzed using Western blot in pMU- and pMC-treated 4910 and 5310 glioma xenograft cells. Hypoxia assoaciated, HIF-1a expression was
analyzed in both cell types after pMU and pMC treatments. GAPDH shows equal loading. C. Immunocytochemistry analysis was carried out to show
co-localization of pATM and cH2AX foci in pMU- and pMC-treated 5310 glioma xenograft cells along with control and pSV. pATM expression can be
visualized as red dots and cH2AX foci as green spots. Merged image shows co-localization as yellow to orange spots. Magnification 606, Bar=10 mm.
Each experiment was repeated 3 times.
doi:10.1371/journal.pone.0026191.g003
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(Figure 3C). Pro-survival signals mediated by ERK and AKT were
downregulated in pMU- and pMC-treated glioma cells as
compared to untreated cells (Figure 3B). These results are
consistent with earlier reported studies wherein inhibition of
AKT and ERK impairs DNA repair in cancer [28,29]. Hypoxia
inducing factor – 1 alpha (HIF-1A), is markedly reduced in pMU-
and pMC-transfected glioma cells compared to control samples
(Figure 3B). Taken together, our results indicated a reduced HR
repair in pMU- and pMC-treated 4910 and 5310 cells.
pMU and pMC treatment results in DNA damage
accumulation and apoptosis
Based on the aforementioned results, we hypothesized that reduced
DDR in pMU- and pMC-treated glioma cells might result in
accumulated damaged DNA. To test this hypothesis, we assessed
accumulated DNA DSBs by comet assay. Comet tail length was
increasedin pMU-andpMC-treatedgliomacellscomparedtocontrol
and pSV, indicating the accumulation of DSBs (Figure 4A). Figure 4B
is a representative bar graph showing a significant increase in comet
tail length in pMU- and pMC-treated 4910 and 5310 glioma cells.
Figure 4. Accumulation of double strand breaks in MU and MC knockdown 4910 and 5310 human glioma xenograft cells. A. Comet
assay showing representative comet tail length observed in pMU and pMC transfected 4910 and 5310 glioma xenograft cells along with control and
pSV samples. Magnification 406, Bar=20 mm. B. Representative bar graph showing comet tail length in pMU- and pMC-treated 4910 and 5310
glioma cells. Error bars indicate 6SD. * significant at p,0.05 Vs control. C. FACS analysis shows cell cycle distribution in pMU- and pMC-treated 4910
and 5310 glioma xenograft cells D. Bar graph shows representative percentage of apoptotic cells in pMU- and pMC-treated verses untreated glioma
cells. Error bars indicate 6SD. * significant at p,0.05 Vs control. E. FACS analysis showing dot plot of gated cH2AX expression and DNA content in
different phases of cell cycle in pMU- and pMC-treated 4910 glioma cells. F. After gating cH2AX expression, its expression in sub G0-G1,G 1, S and G2-M
phases was divided and shown in different shades of gray in pMU and pMC transfected cells compared to pSV. G. Bar graph showing number of cells
expressing cH2AX in sub G0-G1,G 1, S and G2-M phase in pMU- and pMC-treated 4910 glioma xenograft cells along with pSV. 10,000 cells were
analyzed during each process. Error bars indicate 6SD. * significant at p,0.05 Vs control. H. Western blot analysis of cH2AX shows expression of
cH2AX in pMU and pMC transfected 4910 and 5310 glioma cells along with control and pSV. GAPDH shows equal loading. Each experiment was
repeated 3 times.
doi:10.1371/journal.pone.0026191.g004
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4910 and 5310 cells exhibited significant increase in sub G0-G1
cells (apoptotic cells) (Figure 4C). 38–45% of cells were in the
apoptotic phase in pMU- and pMC-transfected 4910 and 5310
human glioma xenograft cells as compared to ,5% of control and
pSV-treated cells (Figure 4D). To further evaluate the expression
of cH2AX, Western blotting and FACS analysis were carried out.
Increased expression of cH2AX was observed in both pMU- and
pMC-treated 4910 and 5310 glioma cells compared to control and
pSV (Figure 4H). Analysis of cH2AX expression and DNA
content by FACS revealed an increased accumulation of cH2AX
expression in G1,S ,G 2-M and sub G0-G1 in MU- and MC-
treated glioma cells compared to pSV (Figure 4E). Figure 4F,
shows the gated cH2AX expression divided into sub G0-G1,G 1,S
and G2-M phases of the cell cycle in different shades of grey colors
after pMU- and pMC-treatment compared to pSV. The
maximum accumulation of cH2AX expression was seen in the
sub G0-G1 phase of pMU- and pMC-transfected 4910 glioma cells
(p,0.05) (Figures 4G). Similarly, 5310 glioma treated cells
expressed progressively increased levels of cH2AX in sub G0-G1
compared to pSV (data not shown).
Further, studies on inhibition of DNA PKcs by NU7441 (a DNA
PKcs inhibitor) resulted in significant inhibition of proliferation as
assessed by MTT and BrdU assay (Supplementary Figure S2A).
FACS analysis indicated sub G0-G1 arrest in 4910 glioma xenograft
cells treated with DNA PKcs inhibitor (Supplementary Figure S2B).
Expression of cH2AX in 4910 cells with DNA PKcs, EGFR and
CHK2 inhibitors alone and in combination with CHK2 inhibitor,
showed increased levels of cH2AX compared to untreated cells
(Supplementary Figure S2C). Supplementary Figure S2C depicts
the prominent increase in the expression of cH2AX with the
combined inhibition of DNA PKcs+EGFR+CHK2 compared to
individual treatments. These result clearly demonstrates how pMU
and pMC treatments orchestrate complex signaling in regulating
key proteins leading to accumulation of DSBs. Taken together,
these results indicate that induction of apoptosis after pMU and
pMC treatments is due to accumulated unrepaired DSBs in 4910
and 5310 glioma cells compared to untreated cells.
Expression of HIF-1a, cH2AX and RAD51 under hypoxia
and in combination with irradiation (IR) after pMU and
pMC treatments in glioma cells
GBM forms solid tumors, thus the cells at the core of the tumors
become anaerobic due to hypoxia. Irradiation and chemotherapy
fail to induce DNA damage in GBM cells thus may not result in
DSBs and apoptosis. We have shown the effect of pMU and pMC
shRNA on GBM cells under high oxygen levels (Normoxia) results
in DSBs and apoptosis. Based on above facts, we further examined
the efficiency of the pMU and pMC treatment under hypoxia
along with irradiation (IR). 4910 and 5310 glioma cells showed
clear change in cell morphology after hypoxic conditions
(Supplementary Figure S3A). Cell proliferation assay using BrdU
incorporation showed that pMU and pMC transfection signifi-
cantly decreased proliferation of hypoxia alone, IR alone and
hypoxia+IR exposed glioma cells compared to the respective
controls in 4910 glioma cells (Supplementary Figure S3B). We
observed that glioma cells, when treated with pMU and pMC
constructs under normoxia, hypoxia, normoxia+IR and hypox-
ia+IR reduced the expression and activity of hypoxia inducing
factor 1 alpha (HIF-1a), when compared with pSV and respective
controls in both 4910 and 5310 glioma cells (Figure 5D and
Supplementary Figure S3C).
We determined extent of DNA fragmentation post-transfection
by TUNEL assay. In TUNEL assay, increased TUNEL-positive
cells were observed in pMU and pMC-transfected hypoxia,
normoxia+IR and hypoxia+IR glioma cells compared to respec-
tive controls (Supplementary Figure S3D). The number of
apoptotic cells were counted post-transfection and the percentage
of TUNEL positive apoptotic cells was plotted (Supplementary
Figure S3E). the apoptotic cells were significantly higher in pMU-
and pMC-transfected hypoxia, normoxia+IR, hypoxia+IR cells
when compared to pSV and respective controls (Supplementary
Figure S3E). In addition, to confirm the accumulation of DSBs
primary to apoptosis induction in pMU- and pMC-treated glioma
cells, we detected the cH2AX and PI expression by FACS analysis
in hypoxia, normoxia+IR and hypoxia+IR glioma cells after pMU
and pMC transfection. We found elevated cH2AX expression in
apoptotic cells in pMU- and pMC-treated hypoxia, normoxia+IR
and hypoxia+IR glioma cells compared to respective controls
(Figure 5A, 5B and 5C). Elevation in cH2AX expression was
further confirmed by Western blot analysis in pMU- and pMC-
transfected hypoxia, normoxia+IR and hypoxia+IR cells com-
pared to respective controls (Figure 5D). We noticed IR could
induce the expression of cH2AX in glioma cells with G2-M arrest
but it failed to induce the cH2AX expression under hypoxia in
glioma cells (Figure 5D). FACS analysis showed transfection of
hypoxia, normoxia+IR and hypoxia+IR glioma cells with pMU
and pMC could readily elevate cH2AX expression and induce
apoptosis in hypoxia, normoxia+IR and hypoxia+IR 4910 and
5310 glioma cells (Figure 5A, 5B and 5C). Moreover, there was
increased expression of cH2AX expression in apoptotic cells
compared to respective control samples (Figure 5C). These results
further show how our constructs stabilized radiation induced DNA
damage in hypoxia and induced apoptotic cell death.
Increased expression of Rad51 in hypoxic, normoxia+IR and
hypoxia+IR glioma cells was markedly lowered by pMU and pMC
treatments in glioma cells (Figure 5D). The above results were
assessed by immunocytochemistry, wherein increased cH2AX foci
were observed in pMU- and pMC-transfected glioma cells. In
corroboration with Western blot analysis, lowered Rad51 foci was
seen in pMU- and pMC-treated hypoxia, normoxia+IR, hypox-
ia+IR exposed glioma cells (Figure 5E). These results highlight that
our constructs used in the study impair DNA repair efficiency not
only under normoxia but also under hypoxia alone and in
combination with IR. This finding is particularly interesting from
a clinical standpoint for hypoxia favored radio- and chemo-
resistant solid tumors.
In vivo studies
Aggressive tumor formation was noticed in glioma xenograft
injected mouse brains compared to normal brains. Further,
Hematoxylin and Eosin staining performed on mouse brains
revealed a prominent reduction of tumor growth in pMU- and
pMC-treated mouse brains when compared to the controls
[22,26]. We next pursued to analyze the expression of DDR
related proteins in control, pMU and pMC-treated brain sections.
Immunohistochemical analysis of these brain sections from all the
groups showed decreased expression of DNA PKcs and ATM after
pMU and pMC treatments compared to controls (Figures 6A and
6B). We also noticed a prominent increase in the expression of
cH2AX in pMU- and pMC-transfected cells compared to controls
(Figure 6C). These in vivo results substantiated our in vitro results.
Discussion
GBM has various genetic deletions, amplifications and point
mutations that lead to the activation of signal transduction
pathways involving cell survival and DNA repair pathways [30].
Role of MMP9 and uPAR/Cath B Silencing on NHEJ
PLoS ONE | www.plosone.org 6 October 2011 | Volume 6 | Issue 10 | e26191Figure 5. Effect of pMU and pMC treatments on cH2AX (NHEJ) and Rad51 (HR) expression in hypoxia alone , irradiation (IR) alone
and hypoxia+IR exposed glioma cells. A. FACS analysis shows cell cycle distribution in pMU- and pMC-treated hypoxic, IR and hypoxic+IR
exposed 5310 glioma xenograft cells. 5,000 cells were analyzed during each process. Number(%) represent respective apoptotic cell population in
samples. B. FACS analysis showing dot plot of gated cH2AX expression after pMU and pMC transfection in hypoxic, IR and hypoxic+IR exposed 5310
glioma xenograft cells along with pSV and control. C. Bar graph showing number of cells expressing cH2AX in sub G0-G1,G 1, S and G2-M phase in
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NHEJ, DNA repair and V (D) J recombination. Ku70, Ku80 and
DNA PKcs form the DNA PK complex. Ku’s high specificity to
interact with DNA ends of DSBs initiates the recruitment of DNA
PKcs. Over-expression of DNA repair proteins in GBM elevate
efficiency of these cancer cells to repair DNA damage making
treatment of GBM inherently difficult. Reduced DNA repair
mechanism and/or induction of apoptosis are the possible
interventions to inhibit proliferation of cancer cells including
glioma. Therefore, in the present study, we focused on the DNA
damage response of glioma cells after pMU and pMC treatments.
We demonstrated that transcriptional silencing of MMP9 in
combination with uPAR/cathepsin B inhibited proliferation of
glioma cells compared to controls.
We observed a prominent decrease in the expression of NHEJ
repair machinery proteins after pMU and pMC treatments. Ku70
and Ku80 DNA binding activity after pMU and pMC treatments
were decreased compared to controls. These results clearly suggest
that the initial Ku binding to DSBs, which is a critical step for
recruitment of DNA PKcs in NHEJ repair response is inhibited by
pMU or pMC treatments. Reduced phosphorylation of DNA
PKcs T
2609 in pMU- or pMC- treated glioma cells further
strengthens these results and the earlier reported findings, wherein,
decreased DNA end processing of DSBs was observed by
inhibition of DNA PKcs T
2609 phosphorylation [31].
To gain further insight into the mechanism by which these
constructs retard DNA repair efficiency, we investigated the signal
cascade involved in the regulation of DNA PK activity. Ku80
participates in cellular response to external stimuli and also the
subcellular localization of Ku is controlled by a variety of external
growth regulating stimuli [32,33]. Integrins play a key role in cell
adhesion to ECM. Interaction of integrins with ECM transduces
signals for cell proliferation, adhesion, migration and angiogenesis.
Earlier studies showed co-immunoprecipitation of the b1 integrin
with uPAR [34]. Our present study results show complex
formation of b1 integrin with uPAR, MMP-9 and cath B on cell
surface, as confirmed by immunoprecipitation. Cav-1 has been
shown to co-immunoprecipitate with the b1 integrin and uPAR
[35]. Signaling mediated by this complex can also involve EGFR
[36]. These results demonstrate the complex interplay among
MMP9, uPAR, cathepsin B, b1 integrin and EGFR in regulating
DNA PK activity. cSrc/cav-1 mediated nuclear EGFR internal-
ization is associated with activation of DNA PK [37]. As expected,
expressions of integrins, caveolin 1, cSrc, which are involved in the
perinuclear transport of EGFR were reduced. Further, immuno-
precipitation analysis demonstrated decreased EGFR association
pMU- and pMC-treated hypoxic, IR and hypoxic+IR exposed 4910 and 5310 glioma xenograft cells along with pSV and control. D. Western blot
analysis of cH2AX shows expression of HIF-1a, cH2AX and Rad51 in pMU and pMC transfected hypoxic, IR and hypoxic+IR exposed 5310 glioma cells
along with pSV and control. GAPDH served as loading control. E. Immunocytochemistry analysis was carried out to show formation of cH2AX and
Rad51 foci in pMU- and pMC-treated hypoxic, IR and hypoxic+IR exposed 4910 glioma xenograft cells along with control and pSV. Each experiment
was repeated 3 times.
doi:10.1371/journal.pone.0026191.g005
Figure 6. Immunohistochemistry analysis of paraffin embedded tissue sections prepared from nude mice implanted orthotopically
with glioma cells and treated with pMU and pMC. IHC analysis shows expression of DNA PKcs (A), ATM (B) and cH2AX (C) in both pre-
established 4910 and 5310 glioma tumors treated with pMU and pMC constructs. Magnification 606. Bar=20 mm. Each experiment was repeated 3
times.
doi:10.1371/journal.pone.0026191.g006
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in glioma cells. Moreover, nuclear expression of EGFR was
associated with elevated DNA repair response. In agreement with
the earlier reported data, we also noticed a reduction in the
nuclear expression of DNA PKcs, Ku70, Ku80 and EGFR. These
findings strengthen the involvement of extracellular signaling
mediated through b1 integrin-EGFR signaling resulted in reduced
DNA PK activity, which is important for the NHEJ-mediated
repair mechanism in glioma cells.
In order to assess the relationship between DNA damage
signaling by pMU or pMC treatments and HR repair pathway,
ATM, a protein kinase critical for the response to DNA DSBs, was
assessed [38,39]. RAD51 related proteins acting downstream of
ATM is required to ensure high fidelity of DNA repair by using an
undamaged homologous DNA template to synthesize the
damaged DNA strand [40]. Unrepaired DNA damage could
activate cell-cycle checkpoints to allow sufficient time to repair
damage or alternately, depending on the extent of damage, a
signal may be transduced that initiates a signal cascade leading to a
permanent growth arrest or apoptosis [41–43]. Genetic alteration
of the CHK2 phosphorylation site rendered cells deficient in DSB
repair [44]. As expected, we have noticed a prominent reduction
of ATM, RAD51 and pCHK2 in glioma cells after pMU and
pMC treatments. In addition, expression of survival signaling
proteins pERK, AKT and pAKT were also prominently reduced.
It has been shown that DSBs, if left unrepaired, will lead to cell
death [41]. Not only was the role of Ku established in the NHEJ
repair mechanism, but it was also shown that depletion of Ku80
was associated with increased incidence of DNA DSBs, chromo-
some aberrations and shortening of telomere ends. Downregula-
tion of Ku80 has been shown to suppress spontaneous tumors by
induction of apoptosis [45]. Based on all these observations, we
thought that the anti-proliferative effect of pMU and pMC
treatments could be due to accumulated unrepaired DSBs,
resulting in apoptosis. Hence, we investigated the existence of
DSBs by observing the presence of cH2AX foci in pMU- and
pMC-treated glioma cells. cH2AX has been associated with
induction of apoptosis [46] and it is also proposed that cH2AX
foci correlate with the number of DSBs with a 1:1 ratio. In
agreement with these earlier findings, we noticed an increase in
comet tail length and cH2AX expression in different phases of the
cell cycle, with a maximum percentage of cH2AX positivity in the
sub G0-G1 phase, which indicates the induction of apoptosis in
cells with accumulated DSBs after pMU and pMC treatments.
Our inhibitory studies showed a marked increase in cH2AX
expression when DNA PKcs/EGFR/pCHK2 were inhibited
together, which shows the selective advantage of our constructs
in inducing apoptosis by DSB accumulation and by regulating the
DNA damage response machinery by different signal transduction
pathways.
Solid tumors including GBM has lowered median pO2 levels
(hypoxia) at the core of the tumor compared to surrounding
normal tissue and hypoxia favors glioma tumor progression [47–
49]. DNA radicals generated from radiation must react with
oxygen to form organic peroxides that stabilize the radiation
induced DNA damage [4]. Another important factor for radiation
resistance by glioma cells is its enhanced DNA repair mechanism.
In the case of chemotherapy resistance, the state of hypoxia itself
and distance of the tumor cells from the blood vessel makes the
tumor cells less effective to chemotherapeutic drugs [50–52].
Strategies carried out to exploit tumor hypoxia had some positive
outcome in other cancers, however it was ineffective in GBM
[53,54]. Any intervention at the cellular level could lead to
potentially better therapeutic options for GBM treatment. Our
results demonstrate that silencing of MMP9 in combination with
uPAR/cathepsin B, which are over expressed in gliomas, affects
the expression of cH2AX (NHEJ), RAD51 (HR) and lowers the
activity of HIF-1a. This signaling downregulates the repair
mechanism and sensitizes the glioma cells to undergo apoptosis
under normoxia, hypoxia and in combination with IR. We
observed hypoxia, normoxia+IR and hypoxia+IR glioma cells
over-expressed RAD51 compared to control. This shows how
hypoxia and IR could elevate the expression of repair genes. One
of the interesting findings of our study is the stabilization of IR-
induced DNA damage under hypoxia by pMU and pMC
treatments. This finding is potentially important because normally
IR therapy fails to induce DNA damage under hypoxia; these
findings are further supported by reduced DNA damage response.
In addition to in vitro results, we also observed reduced expression
of DNA PKcs and ATM proteins in vivo in xenograft cells after
pMU and pMC treatments compared to control brain tumor
sections.
Resistance to apoptosis and increased survival signaling are the
major contributors for cancer cell survival. Drugs that target both
of these pathways would provide a greater therapeutic benefit for
cancer patients. Our earlier in vitro and in vivo studies showed a
promising outcome with bicistronic constructs in the treatment of
glioma by induction of apoptosis in cancer cells. The present study
revealed for the first time that silencing MMP9 in combination
with either uPAR or cathepsin B orchestrates a complex signal
cascade to regulate both NHEJ and HR pathways, which are
involved in DSB repair. The suppression of the DNA damage
repair mechanism by these constructs leads to an increase in the
levels of un-repaired DNA lesions where the cell overcomes the
survival signaling by EGFR/AKT and ERK pathways to undergo
apoptosis. Our study clearly demonstrated the potential anti-
proliferative effect of bicistronic constructs pMU and pMC by
reducing repair of DNA damage and inducing apoptosis. Given
the genetic heterogeneity of cancer cells, targeting the gene
products, which have multi-target potential, with similar beneficial
effects under a different tumor microenvironment may prove to be
a better therapeutic method to treat glioma.
Materials and Methods
Ethics statement
The Institutional Animal Care and Use Committee of the
University of Illinois College of Medicine at Peoria, Peoria, IL,
USA, approved all surgical interventions and post-operative
animal care. The consent was written and approved. The animal
protocol number is 851, dated April 23, 2009, and renewed on
March 15, 2011.
Cell lines and chemical reagents
Glioblastoma xenograft cells (4910 and 5310), kindly provided
by Dr. David James of the University of California, San Francisco,
were generated and maintained in mice and were highly invasive
in the mouse brain. At 3–4 passages of xenograft cells from mice,
heterotrophic tumors were frozen and these frozen stocks were
used for further experimental studies up to the 10
th passage to
obtain consistent results. Xenograft cells were maintained in
RPMI 1640 supplemented with 10% FBS (Invitrogen Corpora-
tion, Carlsbad, CA), 50 units/mL penicillin and 50 mg/mL
streptomycin (Life Technologies, Inc., Frederick, MD). Cells were
maintained in a 37uC incubator with a 5% CO2 humidified
atmosphere. For hypoxia induction, cells were incubated at 1.0%
oxygen for 24 hours. 24 hours post-transfection, cells were
irradiated at a single (8 Gy) dose of radiation using the RS 2000
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FL), which was operated at 150 kV/50 mA for the radiation
treatments, and cultured for additional 24 hours. We used the
following antibodies in the present study: DNA PKcs, pDNA PKcs
(T
2609), Ku70, Ku80, EGFR, Caveolin-1, ATM, ATR, CHK2,
pCHK2, cH2AX, SP1, AKT, pAKT, ERK, pERK, b1 integrin,
MMP9, uPAR, cathepsin B and glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) (all from Santa Cruz Biotechnology,
Santa Cruz, CA), pATM, pATR and pBRCA (Cell Signaling,
Danvers, MA). Species-specific secondary antibodies conjugated to
HRP, Alexa Fluor 488, and Alexa Fluor 595 (Invitrogen,
Carlsbad, CA) were used in this study. All transfections were
carried out using FuGene HD transfection reagent according to
the manufacturer’s instructions (Roche Applied Science, Madison,
WI).
Construction of shRNA expressing plasmids, transfection
conditions and inhibitor treatment
Plasmid constructs containing bicistronic shRNAs pMU, pMC
and scrambled vector (pSV) with an imperfect sequence designed
in our laboratory [22,23] were used to transfect the xenograft cells.
Cells were transfected with either plasmid-expressing shRNA
against pMU, pMC or pSV at 70–80% confluence for 48 hours.
For the inhibitor study, cells seeded in a six-well plate were treated
for 24–48 hours with NU7441 (1–10 mM), a potent DNA PKcs
inhibitor, GW2974 (0.5 mM), a potent inhibitor of EGFR, and
NSC 109555 ditosylate (0.2 mM), a selective CHK2 inhibitor.
Cell proliferation and cell cycle analysis
Cell growth rate was determined using MTT assay ([3-(4, 5-
dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide]; Sigma
Aldrich, St. Louis, MO) as described previously [55]. BrdU
incorporation assay was performed (Roche Diagnostics, Indianap-
olis, IN), according to the manufacturer’s instructions. Clonogenic
assay was carried out by seeding 500 cells in 100 mm plates after
the transfection described above, and survival fraction was
calculated based on the colony forming ability of cells after 2
weeks. Fluorescence activated cell sorting (FACS) analysis was
done after 48 hours of transfection as described previously [56].
FACS analysis was done on at least 10,000 cells from each sample
and cell cycle data were analyzed using a FACS Calibur Flow
Cytometer (BD BioSciences, San Jose, CA). FACS analysis for
cH2AX expression and propidium iodide (PI) staining in different
phases of cell cycle were carried out by incubating trypsinized cells
with primary antibody (1:10 ratio) for 1 hour at 37uC followed by
secondary antibody treatment for 30 minutes.
Reverse transcription polymerase chain reaction (RT-PCR)
Total RNA was extracted from transfected cells using TRIZOL
reagent (Invitrogen, CA) according to standard protocol. RNA
(1 mg) was used as a template for reverse transcription reaction
(Roche Applied Science, Indianapolis, IN), followed by PCR
analysis. We used the following sequences for the forward and
reverse primers: DNA PKcs: 59GCCTTAGCACATGCAGA-
TGA 39 (forward) and 59 GCCACTTGACCAGATCCAAT 39
(reverse); Ku70: 59ATGGCAACTCCAGAGCAGGTG 39 (for-
ward) and 59AGTGCTTGGTGAGGGCTTCCA 39 (reverse);
Ku80: 59 TGACTTCCTGGATGCACTAATCGT39 (forward)
and 59TTGGAGCCAATGGTCAGTCG 39 (reverse) and
GAPDH: 59AGCCACATCGCTCAGACACC 39 (forward) and
59GTACTCAGCGGCCAGCATCG 39 (reverse).
Reverse transcriptase PCR was set up using the PCR cycle
[95uC for 5 min, (95uC for 30 sec, 55–60uC for 30 sec, and 72uC
for 30 sec)630 cycles, 72uC for 10 min]. PCR products were
resolved on a 1.6% agarose gel, visualized, and photographed
under UV light.
Immunoblotting and immunoprecipitation assay
For Western blot analysis, equal amounts of protein fraction
were resolved over SDS-PAGE along with standard protein
marker and immunoblotted with primary antibody followed by
HRP-conjugated secondary antibodies. Signals were detected
using the ECL Western blotting detection system (Pierce, Rock-
ford, IL). IgG served as negative control for all the immunoblot analysis. The
specificity of the proteins evaluated by Western blotting were
verified based on its molecular weight as mentioned in
manufacturer’s data sheet and evaluated it against the standard
protein marker (Precision Plus Protein
TM Kaleidoscope Standards,
Bio-Rad, Hercules, CA). Immunoprecipitation assays were carried
out by incubating a minimum of 100–500 mg total cell lysate with
antibody overnight at 4uC on a rotating shaker. Protein A/G
agarose beads (Miltenyi Biotec, Auburn, CA) were added to the
above complex and incubated for 1 hour on ice. Immunoprecip-
itates were eluted using mMac columns according to the
manufacturer’s instructions and were immunoblotted with appro-
priate primary and secondary antibodies.
Subcellular fractionation
Cytoplasmic and nuclear fractions were prepared using an
Active Motif Nclear Extraction Kit according to the manufactur-
er’s instructions (Active Motif, Carlsbad, CA). Harvested cells were
lysed in hypotonic buffer for 30 min at 4uC and centrifuged. The
supernatant was collected as the cytosolic fraction. The nuclear
pellet was re-suspended in complete lysis buffer for 30 min at 4uC
and the nuclear fraction was collected after centrifugation.
Immunoblot analysis was performed for DNA-PKcs, Ku70,
Ku80, EGFR, and lamin B (served as loading control) in the
nuclear fractions. The purity of nuclear extracts was confirmed by
absence of cytoplasmic marker a-tubulin as assessed by Western
blotting (data not shown).
KU70/80 DNA binding activity
Binding efficiency of Ku70 and Ku80 to DSBs was quantified
using a Ku70/Ku80 Active Motif DNA Repair Kit (Carlbad, CA)
according to manufacturer’s instructions. Nuclear protein (1.25–
2.5 mg) was loaded onto oligonucleotide coated 96-well plate and
incubated for 1 hour at room temperature. Ku70 or Ku80
antibodies were added to the wells and incubated for 1 hour. The
binding of Ku to the DSBs was measured spectroscopically at
450 nm absorbance.
Immunofluorescence
Cells grown in two-well chamber slides were washed with PBS,
fixed with ice-cold methanol and permeabilized with 0.3% triton
X followed by blocking with 2% BSA in PBS. Cells were incubated
with primary antibodies or IgG (specific to the subclass of primary
antibody) for either 2 hours at room temperature or overnight at
4uC, washed with PBS, and incubated with Alexa FluorH
conjugated secondary antibodies for 1 hr at room temperature.
Nuclei were counterstained with DAPI and analyzed under a
microscope (Olympus BX61 Fluoview, Minneapolis, MN). IgG
served as negative control.
Comet Assay
Cellular DNA damage was evaluated using a Comet Assay Kit
(Cell Biolabs’ OxiSelect
TM STA-350) according to the manufac-
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DNA damage accumulation was measured against intact DNA.
Results were quantified and normalized to control.
Hypoxia inducible factor - 1 (HIF-1) DNA binding assay
The extracted nuclear fractions described above were used for
the HIF-1 DNA binding assay. HIF-1 binding efficiency to the
hypoxia responsive elements was analyzed using a Trans-AM
HIF Transcription Factor Assay Kit (Active Motif, Carlsbad,
CA). The assay kit contains a 96-well plate coated with
oligonucleotide containing the HIF-1 binding site from the
EPO gene. Active HIF-1 contained in cell extracts selectively
binds to this oligonucleotide and can be revealed by incubation
with antibodies using enzyme-linked immunosorbent assay
technology with absorbance reading. Approximately 10 ug of
nuclear extract was used and analyzed for HIF-1 binding activity
following manufacturer’s instructions.
In situ terminal deoxynucleotidyl transferase dUTP nick
end labeling (TUNEL) assay
The apoptotic cell death population of all treated cells from
4910 and 5310 glioma cells was detected using a TUNEL
Apoptosis Detection Kit (Roche Diagnostics, Indianapolis, IN)
following manufacturers protocol. Cells were incubated in the
TUNEL reaction mixture at 37uC for 1 hour and further
visualized for the incorporated fluorescein under confocal
microscope. Positive control of the TUNEL assay was confirmed
by incubating fixed and permeabilized cells with DNase I for
10 min at room temperature to induce DNA strand breaks, prior
to labeling procedures. Negative control of the TUNEL assay was
confirmed by incubating fixed and permeabilized cells in label
solution (without terminal transferase) instead of TUNEL reaction
mixture.
Immunohistochemistry
Both 4910 and 5310 glioma xenograft cells were injected
intracerebrally into nude mice with a 10 ml aliquot (0.2610
5
cells/ml) under isofluorane anesthesia with the aid of a
stereotactic frame. Tumors were allowed to grow for 10 to 12
days, and the animals were separated into groups (six animals per
group). Alzet mini pumps were implanted for pMMP-9 delivery
at the rate of 0.2 ml/h. The concentration of the plasmid solution
was 2 mg/ml (100 ml per mouse, six mice in each group). After
five weeks or when the control animals started showing
symptoms the mice were sacrificed by intracardiac perfusion,
first with PBS and then with 4% paraformaldehyde in normal
saline. The brains were collected, stored in 10% buffered
paraformaldehyde, processed, embedded in paraffin, and sec-
tioned (5 mm thick) using a microtome from control and
treatment groups. Further, deparaffinization was done following
standard protocol. Antigen retrieval was performed by treating
the sections with citrate buffer at 95 degrees for 15–20 minutes
followed by hydrogen peroxide treatment for 30 minutes. The
sections were rinsed with PBS and blocked with 1% BSA in PBS
to prevent non-specific staining and further incubated with
primary antibodies (1:50 dilution) at 4uC overnight. The sections
were then incubated either with HRP-conjugated or Alexa Fluor
conjugated secondary antibody for 1 h at room temperature and
followed by 3,3 – diaminobenzidine (DAB) or 4,6-diamino-2-
phenylindole (DAPI) solution incubation for 30 min. The
sections were counterstained with hematoxylin to visualize the
nucleus. Slides were mounted and photographed with a CCD
camera attached to a microscope.
Statistical analysis
All data are presented as mean 6 standard deviation (SD) of at
least three independent experiments. Statistical comparisons were
performed using Graph Pad Prism software (version 3.02).
Bonferroni’s post hoc test (multiple comparison tests) was used to
compare any statistical significance between groups. Differences in
the values were considered significant at p,0.05.
Supporting Information
Figure S1 Anti-proliferative effect of pMU and pMC in
4910 and 5310 human glioma xenograft cells. A. BrdU
incorporation assay carried out in both glioma cells in pMU and
pMC-treated cells compared to control and pSV (p,0.05) Vs
control. B. Survival fraction was calculated based on colony
forming ability of transfected 4910 and 5310 glioma cells in pMU
and pMC treated cells compared to untreated. Each experiment
was repeated 3 times. Error bars indicate 6SD. * significant at
p,0.05 Vs control. C. Immunocytochemistry analysis shows
expression of EGFR in pMU and pMC treated 4910 glioma
xenograft cells. Green signal indicate EGFR expression and
nucleus is stained with DAPI. Magnification 606, Bar=20 mm.
Each experiment was repeated 3 times.
(TIF)
Figure S2 Anti-proliferative role of DNA PKcs inhibition
in 4910 and 5310 glioma xenograft cells. A. MTT and BrdU
assay. MTT assay shows dosage effect of DNA PKcs inhibitor-
NU7441 in 4910 glioma xenograft cells. BrdU incorporation assay
shows effect of inhibition of DNA PKcs in 4910 glioma xenograft
cells. Error bars indicate 6SD. * significant at p,0.05 Vs control.
B. FACS analysis showing effect of DNA PKcs inhibitor (NU7441)
in 4910 glioma xenograft cells compared to DMSO control. Each
experiment was repeated 3 times. C. Western blot showing
expression of cH2AX after treatment with DNA PKcs, EGFR and
CHK2 inhibitors alone and in combination in 4910 glioma cells
compared with DMSO and control. GAPDH shows equal
loading.
(TIF)
Figure S3 Effect of pMU- and pMC-treated hypoxic, IR
and hypoxia+IR exposed glioma xenograft cell. A. 4910
and 5310 cell morphology observed in normoxic and hypoxic
conditions. B. BrdU incorporation assay carried out in hypoxic, IR
and hypoxia+IR exposed 4910 glioma cells represent significant
reduction in proliferation of glioma cells in pMU and pMC-
treated cells compared to pSV and control (p,0.05). C. HIF-1a
DNA binding assay performed by using Active motif kit shows
HIF-1a protein binding to oligonucleotide in pMU- and pMC-
treated 4910 and 5310 hypoxic, IR and hypoxia+IR exposed
glioma xenograft cells along with pSV and control. Error bars
indicate 6SD. * significant at p,0.05 Vs control. D. TUNEL
assay showing TUNEL positivity in pMU and pMC treated
hypoxic, IR and hypoxia+IR exposed 4910 glioma cells compare
to pSV and control. E. Bar graph showing percentage of TUNEL
positive cells in pMU- and pMC-treated hypoxic, IR and
hypoxic+IR exposed 4910 and 5310 glioma xenograft cells along
with pSV and control. Error bars indicate 6SD. * significant at
p,0.05 Vs control.
(TIF)
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